Sarcomas of fat and bone: a case report

Miriam Beate Honnicke1 · Lars Tharun2 · Malte Maria Sieren1 · Jörg Barkhausen1

Received: 30 December 2021 / Accepted: 3 March 2022
Published online: 06 April 2022
© The Author(s) 2022

Abstract
Osteosarcomas are the most common primary malignant bone tumors and are classified by the WHO into several intramedullary and surface subtypes. One of these is the rare parosteal osteosarcoma. Liposarcomas are the second most common soft tissue sarcoma and are classified into several types ranging from intermediate to high grade tumors. In one of our recent patients we found an unusual combination of a parosteal osteosarcoma and a large fatty component, which fluorescence-in-situ-hybridization revealed as liposarcoma. Radiologists, pathologists, and surgeons should consider the possibility of bone and soft tissue malignancies consisting of different components, as this may be of paramount importance for oncologically complete resection.

Keywords Parosteal osteosarcoma · Osteoliposarcoma · Liposarcoma with osteosarcomatous component · MDM 2 · CDK 4

Abbreviations
LPS Liposarcoma
ALT/WDLPS Atypical lipomatous tumor/well differentiated liposarcoma
DDLPS Dedifferentiated liposarcoma
OS Osteosarcoma
POS Parosteal osteosarcoma
c-POS Conventional parosteal osteosarcoma
DPOS Dedifferentiated parosteal osteosarcoma
MDM 2, CDK 4 Cell cycle oncogenes: murine double minute type 2, cyclin-dependent kinase 4
FISH Fluorescence in situ hybridization

1 Introduction
Osteosarcoma is a common primary malignant bone tumor and is classified into multiple subtypes: conventional (osteoblastic, chondroblastic, fibroblastic), low-grade central, teleangiectatic, small cell, surface (parosteal, periosteal, high-grade surface) and secondary types [1]. Parosteal osteosarcoma (pOS) is a rare low-grade osteosarcoma and accounts for only up to 5% of osteosarcomas, typically manifesting in the 2nd to 4th decade of life. Diagnosis is made and treatment planned through the combination of imaging and histopathologic findings [2].
Liposarcoma is a primary malignant mesenchymal tumor and is also classified by the WHO into subtypes: atypical lipomatous tumor (ALT) / well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid liposarcoma, pleomorphic liposarcoma and myxoid pleomorphic liposarcoma [1].

In parosteal osteosarcoma as well as ALT/WDLPS and DDLPS two cell cycle oncogenes localized on the chromosomes 12q14-15, murine double minute type 2 (MDM2) and cyclin-dependent kinase 4 (CDK4), are amplified and overexpressed [3, 4], whereas this is not the case in high grade osteosarcoma and pleomorphic liposarcoma [1]. MDM2 and CDK4 can be analyzed immunohistochemically, the detection of an amplification can be further improved by fluorescence in situ hybridization (FISH) analysis which is more sensitive than immunohistochemistry [5].

Our patient showed the typical imaging signs of parosteal osteosarcoma with central to peripheral dense calcification and a cleavage plane, but additionally large radiolucent areas corresponding to fatty tissue in MRI. Fluorescence-in-situ-hybridization revealed MDM2-amplification in the osteosarcomatous as well as the lipomatous component.

The neoplastic nature of a peritumoral fat accumulation may escape detection. Since the rate of recurrence in incomplete or marginal excision is high [6] our aim is to raise awareness to this possibility in order to plan complete oncologic resection.

2 Case report

We present the case of a Caucasian woman in her 20s referred to our Department of Orthopedic surgery. At the time of presentation her BMI was 28.7 with a weight of 88 kg and a height of 175 cm. She had been experiencing pain in her left upper arm and shoulder for 5 months. Physical examination showed a tender, mostly firm mass of the left upper arm, a slightly impaired range of motion and was otherwise unremarkable. Laboratory tests did not show any pathological results. Because of growing discomfort and a slightly impaired range of motion her primary care physician initiated an X-ray and a subsequent MRI.

The radiograph (Fig. 1) depicted a large mass encasing the proximal left humerus. A thin lucent line next to the greater trochanter indicated a parosteal process. An infiltration into the humerus seemed possible. The matrix was mainly densely osteoblastic, but there was a large focal lucency suggestive of fatty tissue. The suggested diagnosis was parosteal osteosarcoma. The consecutive MRI confirmed considerable amounts of fat within or directly adjacent to the tumor. However, a substantial marrow reaction/infiltration raised doubts about the initial diagnosis and a high-grade osteosarcoma was suspected. Due to the significantly increased risk of metastasis an additional FDG-PET-CT was performed. The examination revealed a moderate focal FDG-uptake (standardized uptake value 4–8) especially at the proximal margins of the lesion. No other foci of pathological uptake were detected, making metastases unlikely (Fig. 2). Based on the imaging findings an open biopsy was carried out. The seven biopsied areas included the extraosseous tumor lateral, proximal intramedullary tissue ventral and dorsal, intramedullary tissue distal, intramedullary fluid and peritumoral fat. The lipomatous tumor component appeared as regular locoregional fatty tissue on conventional microscopy (Fig. 3a). The fluorescence-in-situ-hybridization revealed MDM2-amplification in the intra- and extramedullary as well as the lipomatous component, though, thus confirming a liposarcomatous transdifferentiation of the parosteal osteosarcoma (Fig. 3b). The diagnosis of a low grade parosteal osteosarcoma was confirmed from the extraosseous and the intramedullary matrix-forming component (Fig. 4a and b).

Basal margins of the lesion depicting the low signal of the sclerotic mass adjacent to a large fatty component in the MRI and the moderate FDG-uptake. Biopsies were performed in different areas of the tumor including regions with the highest gadolinium as well as FDG uptake.

3 Discussion

A liposarcomatous component in a parosteal osteosarcoma has only been described in two other patients.

Larousserie et al. [7] present a parosteal osteosarcoma in the humerus with peripheral fatty tissue, bone marrow infiltration could not be confirmed or ruled out. MDM2 analysis could not be performed but CDK4 was overexpressed in both tumor components, confirming the sarcomatous nature of each and ruling out metaplasia of the fatty component.

Sohier et al. [8] report a patient with pOS in the tibia first operated on in 1999 and with recurrence in 2011. During the second operation an adipose mass deemed as an incidental lipoma next to the pOS was removed. Since F. Larousserie
as one of the authors had encountered a similar entity before, an extensive analysis was performed proving the sarcomatous nature of both components. They discuss three hypotheses about the pathogenesis of this mixed-component tumor, two considering a phenotype switch and a third proposing a common precursor.
Li et al. [9] report one patient with parosteal osteosarcoma of the tibia with two areas of fatty tissue in the tumor in CT imaging. Bone marrow infiltration is not described, an MRI was not performed. The histologic diagnosis was pOS with focal fatty metaplasia, MDM2 and CDK4 were not analyzed. It seems probable that the liposarcomatous component has been missed in this case.

In our own patient the fatty tissue was quite prominent, which initially even raised doubts to the imaging diagnosis of parosteal osteosarcoma. The final diagnosis of two sarcomatous entities or liposarcomatous transdifferentiation of the parosteal osteosarcoma was only possible based on the detection of the MDM2-amplification in fluorescence-in-situ-hybridization.

We summarized all four cases in Table 1. They show that a fatty component in or next to a parosteal osteosarcoma is something radiologists, pathologists and surgeons should look out for. It might well be underdiagnosed because fatty tissue is often unsuspicious on macroscopic observation, imaging and even conventional microscopy. Therefore, histologic analysis should always include FISH-analysis for MDM2 and CDK4.

The coexistence of lipomatous and osseous tissue in sarcomas has often been described and has so far been classified in liposarcomas. Liposarcomas of bone (also titled osteoliposarcomas or malignant mesenchymomas) were initially reported in 1934 [10]. They are quite rare, most are reported to be pleomorphic and as far as they have been analyzed they were reported MDM2 and CDK4 negative [11, 12].
Liposarcomas with osteogenic differentiation are well known and fall in the category of dedifferentiated liposarcoma, the two most common forms of heterologous differentiation in dedifferentiated liposarcoma are myogenic and osteosarcomatous/chondrosarcomatous [13], they show MDM2 amplification.

Whether parosteal osteosarcoma with a liposarcomatous component can be classified into one of the existing subtypes or is a new type of bone tumor as proposed by Larousserie [7] remains open to discussion.

4 Summary

Parosteal osteosarcoma combined with perifocal fatty tissue has now been described in four patients. In one case it was judged to be metaplastic fatty tissue adjacent to pOS, but liposarcoma might have been missed due to lack of testing. In our own patient the liposarcoma was only diagnosed by fluorescence-in-situ-hybridization. In three patients the existence of two sarcomatous entities or liposarcomatous transdifferentiation of the parosteal osteosarcoma was proven.

The incidence is probably higher, as peritumoral fatty tissue may not arouse suspicion.

Since the rate of recurrence in incomplete or marginal excision is high, it seems essential to look for a fatty component as part of parosteal osteosarcomas to achieve complete oncologic resection. Even inconspicuous fatty tissue should be biopsied and analyzed for MDM2-amplification, preferably by fluorescence-in-situ-hybridization.
| Case     | Year | Age | Gender | Location          | Description                | Diagnosis                        |
|----------|------|-----|--------|-------------------|----------------------------|----------------------------------|
| Larousserie | 2011 | 34  | f      | Prox humerus parosteal | Peripheral, monofocal, CDK4 positiv, MDM2 not possible | Parosteal osteosarcoma with large fatty component |
| Li       | 2018 | 34  | f      | Prox tibia parosteal | Peripheral, bifocal, "Focal fatty metaplasia", MDM2 and CDK 4 not done | Parosteal osteosarcoma with fatty component |
| Sohier   | 2020 | 23  | f      | Prox tibia parosteal | Peripheral, bifocal, MDM2, CDK4 positiv fat, bone not possible | Parosteal osteosarcoma with fatty component |
| Own case | 2021 | 23  | f      | Proximal humerus, parosteal | Peripheral, bifocal, MDM2, CDK4 positiv fat and bone | Parosteal osteosarcoma with large fatty component |
Author contributions MBH wrote the main manuscript, acquisition and interpretation of data. LT acquisition and interpretation of data. MMS revising the article critically. JB final approval of the version to be published. All authors read and approved the final manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Ethics approval and consent to participate Informed consent was obtained from the subject described in this report.

Competing interests The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020.
2. Harper K, Sathiadoss P, Saifuddin A, Sheikh A. A review of imaging of surface sarcomas of bone. Skeletal Radiol. 2021;50(1):9–28.
3. Franceschini N, Lam SW, Cleton-Jansen A-M, Bovée JVMG. What’s new in bone forming tumours of the skeleton? Virchows Arch. 2020;476(1):147–57.
4. Aleixo PB, Hartmann AA, Menezes IC, Meurer RT, Oliveira AM. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol. 2009;62(12):1127–35.
5. Sirvent N, Coindre J-M, Maire G, Hostein I, Keslair F, Guillou L, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007;31(10):1476–89.
6. Kumar VS, Barwar N, Khan SA. Surface osteosarcomas: diagnosis, treatment and outcome. Indian J Orthop. 2014;48(3):255–61.
7. Barnard L. Primary liposarcoma of bone. Arch Surg. 1994;29(4):560.
8. Tiemeier GL, Brown JM, Pratap SE, McCarthy C, Kastrenopoulou A, Bradley K, et al. Pleomorphic liposarcoma of bone: a rare primary malignant bone tumour. Clin Sarcoma Res. 2018;8:2.
9. Hamlat A, Saikali S, Gueye E-M, Le Strat A, Carsin-Nicol B, Brassier G. Primary liposarcoma of the thoracic spine: case report. Eur Spine J. 2005;14(6):613–8.
10. Yamashita K, Kohashi K, Yamada Y, Ishii T, Nishida Y, Urakawa H, et al. Osteogenic differentiation in dedifferentiated liposarcoma: a study of 36 cases in comparison to the cases without ossification. Histopathology. 2018;72(5):729–38.
11. Li N, Li L, La Tegola L, Ding Y, Liu W, Niu X, et al. Parosteal osteosarcoma with focal fatty metaplasia: a case report. Radiol Case Rep. 2018;14(2):200–3.
12. Larrousserie F, Chen X, Ding Y, Kreshak J, Cocchi S, Huang X, et al. Parosteal osteosarcoma: a new bone tumor (from imaging to immunophenotype). Eur J Radiol. 2013;82(12):2149–53.
13. Sohier P, Rodrigues M, Anrat P, Feydy A, Larrousserie F. Parosteal osteosarcoma associated with a low-grade component mimicking well-differentiated liposarcoma: a case report. Skeletal Radiol. 2021;50(1):243–8.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.